Pepgen (PEPG) Stock
Small biotech company developing genetic treatments for rare diseases. Here's the price, business snapshot, and what's worth knowing about Pepgen in October 2026.
PEPGEN Inc (PEPG) is a small-cap biotechnology company with a market capitalisation around $335 million. The business focuses on developing therapeutic candidates and related technologies typical of biopharmaceutical firms, with progress driven by research and development, clinical milestones and potential partnerships. For investors, key considerations include the company’s pipeline stage, cash runway and any upcoming trial readouts or regulatory events that can materially affect the share price. Small-cap biotech stocks can be volatile and outcomes are often binary — success or setback in clinical programmes can cause significant moves. Monitor financial reports, funding needs and collaboration agreements. This summary is for general educational purposes only and does not constitute investment advice; speak to a regulated financial adviser to assess suitability. Past performance is not indicative of future results and capital is at risk.
Pepgen (PEPG) Stock Forecast
Analyst price target, next 12 months
$11.55
+358.3% vs today's $2.52
Price range over the last 12 months
Close to its 12-month low
Analysts covering Pepgen have a consensus 12-month target of $11.55, above the current price of $2.52.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 16 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pepgen's stock with a target price of $11.55, indicating good potential for growth.
Financial Health
Pepgen Inc shows solid financial performance with positive cash flow and a healthy book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Matter
Trial readouts and regulatory steps can sharply move the stock; outcomes are uncertain and can be binary.
R&D And Cash Needs
Research and development are capital intensive — monitor cash runway and potential dilution from future financing.
Partnerships And Licensing
Collaborations can provide funding and validation, but terms and commercial success vary; assess agreements carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
